Galapagos NV (NASDAQ:GLPG)

56.69
Delayed Data
As of Jul 01
 +0.89 / +1.59%
Today’s Change
46.41
Today|||52-Week Range
72.11
+2.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.7B

Company Description

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Contact Information

Galapagos NV
Industriepark Mechelen Noord
Mechelen Brussels Region 2800
P:(321) 534-2900
Investor Relations:
(249) 558-4663

Employees

Shareholders

Mutual fund holders6.85%
Other institutional12.50%
Individual stakeholders--

Top Executives

Paulus StoffelsChairman & Chief Executive Officer
Bart FiliusPresident, Chief Operating & Financial Officer
Walid Abi-SaabChief Medical Officer
Andre HoekemaChief Business Officer
Michele MantoChief Commercial Officer